Welcome to our dedicated page for Personalis SEC filings (Ticker: PSNL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Personalis, Inc. filings document regulatory disclosures for a Nasdaq-listed precision oncology genomics company focused on sequencing, data analysis and cancer monitoring tests. Form 8-K reports cover quarterly and annual operating results, clinical test revenue, business highlights, financial guidance and material events involving NeXT Personal and related reimbursement decisions.
The company’s filings also disclose Medicare coverage and rate determinations for NeXT Personal breast and lung cancer surveillance tests, officer appointments and related compensation arrangements, and the registered common stock traded under PSNL. Proxy materials cover board matters, shareholder voting items, executive compensation and governance disclosures for the public company.
Personalis, Inc. reported fourth quarter and full year 2025 results and issued 2026 guidance, highlighting rapid growth in its clinical testing business alongside continued losses. Full year 2025 revenue was $69.6 million, down from $84.6 million, with a net loss of $81.3 million. However, clinical test volume surged nearly 400% to 16,233 tests, and Q4 clinical test revenue rose to $0.9 million from $0.2 million. The company ended 2025 with about $240 million in cash, cash equivalents and short-term investments, including $109 million of ATM proceeds. For 2026, Personalis guides to revenue of $78–$80 million, clinical revenue of $10–$11 million on 43,000–45,000 tests, and expects a net loss of about $105 million and cash usage of about $100 million as it invests behind 5x projected clinical revenue growth.
Personalis, Inc. executive Aaron Tachibana, the company’s CFO and COO, reported an acquisition of derivative securities through equity compensation. On February 23, he became entitled to 15,000 stock options at an exercise price of $0.00 per share, held as direct ownership.
According to the disclosure, this amount reflects the vesting of a performance stock option originally granted on March 15, 2024, after a specified reimbursement milestone was satisfied. The filing records this as a grant or award-type acquisition rather than an open-market purchase or sale of Personalis common stock.
Personalis, Inc. reported that Chief Medical Officer and EVP Richard Chen acquired 15,000 stock options through the vesting of a performance-based award. The options relate to a performance stock option originally granted on March 15, 2024, which vested after a specified reimbursement milestone was achieved, bringing his directly held derivative position to 15,000 options.
Personalis, Inc. reported an insider equity transaction for Stephen Michael Moore, its SVP and Chief Legal Officer. He acquired 8,333 stock options, recorded as a grant or award at a reported price of $0.0000 per option.
According to the footnote, this reflects the vesting of a performance stock option originally granted on March 15, 2024, after a specified reimbursement milestone was satisfied. Following this transaction, Moore held a total of 8,333 stock options directly.
Personalis, Inc. reported that President and CEO Christopher M. Hall acquired rights to 33,333 shares through the vesting of a performance stock option. The option tranche vested on February 23, 2026 after the company met a specified reimbursement milestone tied to the original grant made on March 15, 2024.
The transaction is coded as a grant or award acquisition, with no cash paid per option at vesting. Following this vesting event, Hall holds 33,333 stock options related to this performance-based award as direct ownership.
Ameriprise Financial, Inc. filed a Schedule 13G reporting a significant ownership stake in Personalis, Inc. common stock. As of 12/31/2025, Ameriprise reports beneficial ownership of 6,287,151 shares, representing 7.1% of Personalis’ outstanding common stock.
Ameriprise reports no sole voting or dispositive power, with all reported voting and dispositive power shared across these holdings. The firm states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Personalis, and disclaims beneficial ownership of the shares reported.
Tempus AI, Inc., a 10% owner of Personalis, Inc., reported a series of open-market purchases of Personalis common stock. Between November 18 and December 22, 2025, Tempus AI bought multiple blocks of shares at weighted-average prices generally between $7.67 and $11.00, as detailed in the transaction table and footnotes.
After the latest reported trade on December 22, 2025, Tempus AI beneficially owned 13,039,067 shares of Personalis common stock, held directly. The footnotes explain that each reported price is a weighted average for numerous trades within stated intraday price ranges.
Personalis, Inc. investor Orin Hirschman and affiliated AIGH entities report a passive ownership position below 5% of the company’s common stock. The filing shows Mr. Hirschman beneficially owning 3,416,720 shares, representing 3.8% of the outstanding common stock, with sole voting and dispositive power.
AIGH Capital Management LLC separately reports beneficial ownership of 2,900,000 shares, or 3.3% of the class, also with sole voting and dispositive power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Personalis.
Personalis, Inc. insider trading report: Chief Financial Officer and Chief Operating Officer Aaron Tachibana exercised stock options for 1,201 shares of common stock at $9.16 per share on January 22, 2026, then sold 1,201 shares of common stock at $11.50 per share the same day. After these transactions, he held 164,458 shares of common stock directly and 107,631 stock options. The filing notes that the sale and option exercise were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025, which is designed to allow insiders to trade shares according to a set schedule.
A shareholder has filed a notice of proposed sale for 40,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/22/2026. The filing lists an aggregate market value of 386,000.00 for these shares and identifies the securities as listed on NASDAQ. The shares to be sold were acquired on 01/22/2026 via an exercise of stock options, paid for in cash on the same date. Over the prior three months, the filing reports that 103,668 common shares were sold for gross proceeds of 1,117,065.47 in Rule 10b5-1 sales for AARON L TACHIBANA.